Mitoimmune Therapeutics Inc.

Mitoimmune Therapeutics Inc. is a clinical stage biotech company with a focus on developing drugs for diseases with high unmet needs using mitochondria/ferroptosis based approaches. Their molecules, based on the MIT platform, are mitochondria-targeted ferroptosis inhibitors that have shown to recover intracellular homeostasis of iron, calcium, redox, and immune, and to preserve antioxidant systems such as GPX4 under pathological conditions. Founded in 2018 and headquartered in South Korea, the company recently secured a KRW27.50B Series B investment on 26 February 2021 from a consortium of investors including Aju IB Investment, KB Investments, Korea Development Bank, IMM Investment, Timewise Investment, BNH Investment, KB Securities, SL Investment, Quantum Ventures Korea, and Orion Capital Management. MitoImmune's innovative approach and recent funding indicate both market potential and investor confidence in their mission to address critical healthcare challenges.